- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Langhorne Today
By the People, for the People
Savara Receives U.K. Regulatory Approval for MOLBREEVIx
The MHRA has accepted the company's application for its rare lung disease treatment.
Apr. 7, 2026 at 1:43pm
Got story updates? Submit your updates here. ›
A precision medical device symbolizes Savara's efforts to expand access to innovative treatments for rare lung diseases.Langhorne TodaySavara, a biopharmaceutical company, has announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the company's application for its rare lung disease treatment, MOLBREEVIx. This marks a significant milestone for Savara as it seeks to expand access to its innovative therapy in the European market.
Why it matters
The approval of MOLBREEVIx by the MHRA is a crucial step for Savara, as it will allow the company to offer its treatment to patients in the U.K. suffering from rare lung diseases. This is particularly important given the limited treatment options currently available for these conditions.
The details
MOLBREEVIx is Savara's lead product candidate, a novel therapy designed to treat rare and serious lung diseases. The MHRA's acceptance of Savara's application indicates that the regulatory agency will now review the data and information provided by the company, with the goal of potentially granting marketing authorization for the treatment.
- Savara announced the MHRA's acceptance of the MOLBREEVIx application on April 7, 2026.
The players
Savara
A biopharmaceutical company focused on developing and commercializing therapies for rare and serious lung diseases.
MHRA
The U.K. Medicines and Healthcare Products Regulatory Agency, the government body responsible for regulating and supervising the safety, quality and efficacy of medicines in the United Kingdom.
What’s next
If the MHRA approves MOLBREEVIx, Savara will be able to make the treatment available to patients in the U.K. suffering from rare lung diseases.
The takeaway
The MHRA's acceptance of Savara's application for MOLBREEVIx is a positive step forward in expanding access to innovative treatments for rare and serious lung diseases in the U.K. market.
